Brokerages Set CeriBell (NASDAQ:CBLL) PT at $31.00

CeriBell (NASDAQ:CBLL) has been assigned a consensus rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $31.00.

Several research analysts have weighed in on the company. Canaccord Genuity Group began coverage on CeriBell in a research report on Tuesday. They set a “buy” rating and a $30.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a research report on Tuesday. They issued an “overweight” rating and a $32.00 price objective for the company. Bank of America began coverage on shares of CeriBell in a report on Tuesday. They issued a “buy” rating and a $32.00 target price on the stock. Canaccord Genuity Group assumed coverage on CeriBell in a research note on Tuesday. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, William Blair began coverage on CeriBell in a report on Tuesday. They set an “outperform” rating on the stock.

CeriBell Trading Up 4.2 %

Shares of NASDAQ CBLL opened at $28.95 on Tuesday. CeriBell has a fifty-two week low of $23.00 and a fifty-two week high of $29.53.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.